Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma
Open Access
Abstract
BACKGROUND: The combination of paclitaxel, oral estramustine phosphate (EMP), and carboplatin (TEC) has shown antitumor activity in patients with castrate, metastatic prostate carcinoma. To improve the therapeutic efficacy and reduce the toxicity of TEC, the authors substituted intravenous (i.v.) EMP for oral EMP based on single‐agent studies demonstrating an improved safety profile with i.v. EMP.METHODS: Patients with progressive, castrate, metastatic prostate carcinoma were treated with up to 6 4‐week cycles of i.v. EMP (500–1500 mg/m2 per week), paclitaxel (100 mg/m2 per week), and carboplatin (target area under the curve = 6 mg/mL every 4 weeks).RESULTS: Thirty patients were treated in 6 dose cohorts. Deep venous thrombosis occurred in 5 of 30 patients (17%). Other common Grade 3/4 (according to National Cancer Institute Common Toxicity Criteria) toxicities included hepatic toxicity (23%) and leukopenia (24%). Posttherapy prostate specific antigen declines > 50% were seen in 18 of 30 patients (60%), and declines > 80% were seen in 15 of 30 patients (50%). Eleven of 17 patients (65%) with measurable soft tissue disease achieved a partial response. Four of 27 patients (15%) with osseous metastases demonstrated improvement on bone scan.CONCLUSIONS: Intravenous EMP was administered safely with paclitaxel and carboplatin and produced clinical outcomes similar to the outcomes achieved with the TEC regimen. Substitution of i.v. EMP for the oral formulation was found to result in a lower incidence of severe nausea but increased hepatic toxicity. Cancer 2003. © 2003 American Cancer Society.Keywords
This publication has 17 references indexed in Scilit:
- Phase II Study of Docetaxel, Estramustine, and Low-Dose Hydrocortisone in Men With Hormone-Refractory Prostate Cancer: A Final Report of CALGB 9780Journal of Clinical Oncology, 2001
- Paclitaxel, Estramustine Phosphate, and Carboplatin in Patients With Advanced Prostate CancerJournal of Clinical Oncology, 2001
- Clinical states in prostate cancer: toward a dynamic model of disease progressionUrology, 2000
- Phase II Trial of Oral Estramustine, Oral Etoposide, and Intravenous Paclitaxel in Hormone-Refractory Prostate CancerJournal of Clinical Oncology, 1999
- Phase I Trial of Docetaxel With Estramustine in Androgen-Independent Prostate CancerJournal of Clinical Oncology, 1999
- Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinomaAnnals of Oncology, 1999
- Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer.Journal of Clinical Oncology, 1997
- Evidence for a non‐estrogenic cytostatic effect of estramustine on human prostatic carcinoma cells in vivoThe Prostate, 1992
- Plasma Concentrations of Estramustine Phosphate and Its Major Metabolites in Patients with Prostatic Carcinoma Treated with Different Doses of Estramustine Phosphate (Estracyt®).Scandinavian Journal of Urology and Nephrology, 1981
- Studies on Phenolic Steroids in Human Subjects. XIV. Fate of a Nitrogen Mustard of Estradiol-17βThe Journal of Clinical Endocrinology & Metabolism, 1975